Dicerna Pharmaceuticals Inc. (NASDAQ:DRNA) traded at a new 52-week high today of $29.70. So far today approximately 106,000 shares have been exchanged, as compared to an average 30-day volume of 855,000 shares.
Dicerna Pharmaceuticals Inc is a biotechnology company involved in the discovery and development of innovative treatments for rare inherited diseases affecting the liver, along with cancers, and other therapeutic areas to address liver problems. The company is using ribonucleic acid interference (RNA) technology platform to develop its products. The product candidates are DCR-PHXC (for primary hyperoxaluria), DCR-undisclosed (for orphan genetic disease), DCR-PCSK9 (for cardiovascular disease), and DCR-HBV (for hepatitis B virus) among others.
In the past 52 weeks, shares of Dicerna Pharmaceuticals Inc. have traded between a low of $11.75 and a high of $29.70 and is now at $28.91, which is 146% above that low price.
Potential upside of 2.3% exists for Dicerna Pharmaceuticals Inc., based on a current level of $28.91 and analysts’ average consensus price target of $29.57.
Receive IBN Spotlights – “Bite Size” Small, Mid and Large-Cap Technical Indicator Alerts
To stay connected with our complimentary IBN Spotlights, please visit https://IBN.fm/connected
About InvestorBrandNetwork (IBN)
InvestorBrandNetwork (IBN) consists of 50+ trusted financial brands introduced to the investment public over the course of 15+ years. Through these brands, IBN provides (1) access to our Investor Press Release Wire Solutions via InvestorWire (IW) to reach all target markets, industries and demographics in the most effective manner possible; (2) article and editorial syndication to 5,000+ news outlets; (3) enhanced press release solutions via IW to ensure maximum impact; (4) full-scale distribution to an enormous social media audience that includes millions of followers; and (5) a full array of corporate communications solutions focused on the IBN Podcast Series. With a proven track record serving 500+ client partners, IBN is the key to a more effective market communication campaign.
For more information, please visit https://www.InvestorBrandNetwork.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer